<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">World J Surg Oncol</journal-id>
      <journal-title-group>
        <journal-title>World Journal of Surgical Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1477-7819</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26376781</article-id>
      <article-id pub-id-type="pmc">4573480</article-id>
      <article-id pub-id-type="publisher-id">695</article-id>
      <article-id pub-id-type="doi">10.1186/s12957-015-0695-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Primary pulmonary melanoma: a report of two cases</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Watanabe</surname>
            <given-names>Mototsugu</given-names>
          </name>
          <address>
            <email>mowatanabe@s.okayama-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yamamoto</surname>
            <given-names>Hiromasa</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hashida</surname>
            <given-names>Shinsuke</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Soh</surname>
            <given-names>Junichi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sugimoto</surname>
            <given-names>Seiichiro</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Toyooka</surname>
            <given-names>Shinichi</given-names>
          </name>
          <address>
            <phone>+81-86-235-7435</phone>
            <email>toyooka@md.okayama-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miyoshi</surname>
            <given-names>Shinichiro</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Thoracic, Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558 Japan </aff>
        <aff id="Aff2"><label/>Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558 Japan </aff>
        <aff id="Aff3"><label/>Biobank of Okayama University Hospital, Okayama, 700-8558 Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>9</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>17</day>
        <month>9</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>13</volume>
      <elocation-id>274</elocation-id>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>4</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>9</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Watanabe et al. 2015</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Malignant melanoma is a refractory malignancy with a dismal prognosis. It generally arises from the skin in most cases, and cases of primary pulmonary malignant melanoma are rare and often behave aggressively. We have treated two cases of localized primary pulmonary malignant melanoma using surgical resection. Pulmonary malignant melanomas often metastasize to the brain and liver; one of our cases exhibited metastasis to the cecum at about 8&#xA0;months after surgery. Because cutaneous melanomas often carry activating mutations in the <italic>BRAF</italic> gene (V600E), we performed a <italic>BRAF</italic> mutational analysis using direct sequencing for both of these tumors arising from the lung. However, no <italic>BRAF</italic> mutations were detected. We detected a p53 mutation, which was thought to be a potential somatic mutation, in one of the two cases using a sequencing panel targeting 20 lung cancer-related genes. Although we also checked the expression of programmed death ligand 1 (PD-L1) on the surface of the tumor cells by immunohistochemical testing, neither of our two cases expressed PD-L1. Further molecular analyses may uncover the characteristics of primary pulmonary malignant melanomas.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Primary pulmonary malignant melanoma</kwd>
        <kwd>Target sequencing</kwd>
        <kwd>Surgical resection</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Background</title>
      <p>Malignant melanoma is an often fatal cutaneous neoplasm. As a primary tumor, malignant melanoma of the lung is rare, accounting for only 0.01&#xA0;% of all primary lung tumors [<xref ref-type="bibr" rid="CR1">1</xref>]. To diagnose malignant melanoma as a primary tumor arising from the lung, the absence of primary melanoma lesions at cutaneous or nonpulmonary extracutaneous sites must be demonstrated [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
      <p>Approximately 40 to 60&#xA0;% of cutaneous melanomas carry mutations in the <italic>BRAF</italic> gene (V600E), which leads to the constitutive activation of downstream signaling through the MAPK pathway [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. At present, whether pulmonary malignant melanomas carry <italic>BRAF</italic> mutations has not been reported. Additionally, immunotherapy to inhibit programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway that has a role for immune escape is developed for malignant melanoma [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. It is reported that the efficacy of anti-PD-1 antibody was related to the expression of PD-L1 in tumor cells [<xref ref-type="bibr" rid="CR6">6</xref>]. Here, we describe two cases of possible primary pulmonary malignant melanoma with wild-type <italic>BRAF</italic> and no expression of PD-L1.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <sec id="Sec3">
        <title>Case 1</title>
        <p>A 66-year-old man with hemoptysis was referred to our hospital because of a pulmonary malignant tumor. A bronchoscopy revealed a tumor arising from the right middle lobe bronchus (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>), and a histological diagnosis based on a bronchial biopsy revealed a malignant melanoma. A positron emission tomography-computed tomography (PET-CT) scan revealed no other lesions that could have represented a primary site (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>). A right middle lobectomy with mediastinal and hilar lymphadenectomy was performed. Some tumor cells had melanin in the cytoplasm (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c</xref>). Immunohistochemical analysis showed positive cytoplasmic staining of the tumor cells for HMB-45, Tyrosinase, and MART1, although the expression of TTF-1 in tumor cells was negative. The postoperative course was uneventful. Combination chemotherapy of dacarbazine, nimustine, and vincristine was performed. At the time of the 22&#xA0;months after surgery, he was alive without disease recurrence.<fig id="Fig1"><label>Fig. 1</label><caption><p>Diagnostic images and pathological findings for case 1. <bold>a</bold> A bronchoscopy revealed a tumor arising from the right middle lobe bronchus. <bold>b</bold> PET-CT scan revealed no other lesions that could have represented a primary site. <bold>c</bold> Hematoxylin-eosin staining of the resected tumor, &#xD7;40 (<italic>scale bar</italic>, 100&#xA0;&#x3BC;m). <bold>d</bold> Immunohistochemistry showed negative for PD-L1 staining, &#xD7;40 (<italic>scale bar</italic>, 100&#xA0;&#x3BC;m)</p></caption><graphic xlink:href="12957_2015_695_Fig1_HTML" id="MO1"/></fig></p>
      </sec>
      <sec id="Sec4">
        <title>Case 2</title>
        <p>A 46-year-old woman was found to have an abnormal shadow on a chest X-ray during an annual check-up. A CT and PET-CT scan showed a tumor in the left lower lobe of the lung (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>, <xref rid="Fig2" ref-type="fig">b</xref>). Pathological examination of a specimen obtained during a transbronchial lung biopsy revealed that the tumor was a malignant melanoma (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref>). Because further examinations did not reveal any other tumors that could have been the primary lesion, we diagnosed the lung tumor as a primary pulmonary malignant melanoma. A left lower lobectomy with mediastinal and hilar lymph node dissection was performed. Immunohistochemical staining was negative for S-100 protein, chromogranin, synaptophysin, keratin, and TTF-1 but positive for HMB-45 and vimentin. The postoperative course was uneventful. She refused to receive adjuvant chemotherapy. Eight months after the pulmonary resection, a PET-CT scan showed the uptake of fluorodeoxyglucose in the cecum (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2e</xref>). An ileocecal resection was performed, and the pathological examination indicated that the tumor was considered to be the recurrence of a melanoma.<fig id="Fig2"><label>Fig. 2</label><caption><p>Diagnostic images and pathological findings for case 2. <bold>a</bold> A CT scan shows a large tumor in the left lower lobe of the lung. <bold>b</bold> Preoperative PET-CT scan revealed no other lesions that could have represented a primary site. <bold>c</bold> Hematoxylin-eosin staining of the resected tumor, &#xD7;40 (<italic>scale bar</italic>, 100&#xA0;&#x3BC;m). <bold>d</bold> Immunohistochemistry showed negative for PD-L1 staining, &#xD7;40 (<italic>scale bar</italic>, 100&#xA0;&#x3BC;m). <bold>e</bold> Eight months after the pulmonary resection, PET-CT scan showed the uptake of fluorodeoxyglucose in the cecum</p></caption><graphic xlink:href="12957_2015_695_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec5">
        <title>Molecular profiling</title>
        <p>We determined the <italic>BRAF</italic> mutational status (exons 11 and 15) using direct sequencing in the two tumors. The detailed methods have been described previously [<xref ref-type="bibr" rid="CR7">7</xref>]. However, we did not detect any <italic>BRAF</italic> mutations. Next, we performed a target sequencing analysis using the Human Lung Cancer Panel (Qiagen, Hilden, Germany), which targets 20 lung cancer-related genes including most of the exons in <italic>BRAF</italic>, using the same samples. Although various variants were detected using this analysis, only the p53 mutation (P72R) in case 1 was considered to be a potential somatic mutation after restricting the variants using GeneRead Software (Qiagen, Venlo, Netherlands) as shown in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. P72R mutation has been already reported in bladder and gastric cancers, but there are no reports in lung cancer or malignant melanoma ([<xref ref-type="bibr" rid="CR8">8</xref>], accessed on August 14, 2015).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Mutational status of 20 genes in cases 1 and 2</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene name</th><th>Case 1</th><th>Case 2</th></tr></thead><tbody><tr><td>
<italic>MTOR</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>NRAS</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>PTGS2</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>ALK</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>CTNNB1</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>PIK3CA</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>PDGFRA</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>KIT</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>EGFR</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>MET</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>BRAF</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>CDKN2A</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>PTEN</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>HRAS</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>KRAS</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>RB1</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>AKT1</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>TP53</italic>
</td><td>P72R</td><td>WT</td></tr><tr><td>
<italic>ERBB2</italic>
</td><td>WT</td><td>WT</td></tr><tr><td>
<italic>STK11</italic>
</td><td>WT</td><td>WT</td></tr></tbody></table><table-wrap-foot><p>
<italic>WT</italic> wild type</p></table-wrap-foot></table-wrap></p>
        <p>Furthermore, we also checked the expression of PD-L1 on the surface of the tumor cells by immunohistochemical testing in formalin-fixed, paraffin-embedded tumor specimens with the use of a rabbit monoclonal antihuman PD-L1 antibody. In the previous reports, PD-L1 positivity was defined as at least 5&#xA0;% of tumor cells showing cell-surface PD-L1 staining of any intensity in a section containing at least 100 tumor cells that could be evaluated [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. According to the definition of PD-L1 positivity by them, neither of our two cases was considered to express PD-L1 (Figs.&#xA0;<xref rid="Fig1" ref-type="fig">1d</xref> and <xref rid="Fig2" ref-type="fig">2d</xref>).</p>
      </sec>
    </sec>
    <sec id="Sec6" sec-type="discussion">
      <title>Discussion</title>
      <p>The total number of operations in general thoracic surgery is increasing year by year in Japan [<xref ref-type="bibr" rid="CR11">11</xref>]. However, there are a few reports about primary pulmonary melanoma [<xref ref-type="bibr" rid="CR2">2</xref>]. There are four clinical criteria that should be satisfied for the diagnosis of primary melanoma of the lung: (1) no previously removed skin tumor, unless the pathology examination did not show malignancy and the slides are still available for reevaluation; (2) no excised ocular tumor; (3) a solitary tumor in the surgical specimen from the lung; and (4) no demonstrable melanoma in other organs at the time of surgery [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Both of our cases fulfill the abovementioned diagnostic criteria.</p>
      <p>Regarding treatment, surgery is necessary for a cure for localized pulmonary malignant melanoma because the effect of chemotherapy on malignant melanoma is limited [<xref ref-type="bibr" rid="CR13">13</xref>]. Even among patients who undergo surgery, the prognosis of patients with malignant melanoma of the lung is generally poor because the lesion often metastasizes soon after surgery. Regarding metastatic spread, primary pulmonary melanomas often metastasize to the brain and the liver [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR14">14</xref>&#x2013;<xref ref-type="bibr" rid="CR16">16</xref>], similar to other types of primary lung cancer. Intriguingly, one of our cases exhibited metastasis to the cecum. To the best of our knowledge, this is the first report describing a malignant melanoma of the lung metastasizing to the cecum.</p>
      <p><italic>BRAF</italic>-activating mutation is a characteristic of malignant melanoma, and molecular-targeted therapy for BRAF has been developed [<xref ref-type="bibr" rid="CR17">17</xref>]. However, our two cases did not exhibit activating mutations in <italic>BRAF</italic>. Considering the fact that the presence of <italic>BRAF</italic>-activating mutations has not been reported in pulmonary malignant melanoma, their features may differ from those of primary skin melanoma. A target sequencing analysis did not detect any possible somatic driver mutations commonly observed in lung cancer [<xref ref-type="bibr" rid="CR18">18</xref>], such as <italic>EGFR</italic>, <italic>HER2</italic>, <italic>KRAS</italic>, <italic>ALK</italic>, <italic>MET</italic>, or <italic>PIK3CA</italic>, suggesting that primary pulmonary malignant melanomas may have different oncogenic pathways from primary lung cancer from the viewpoint of driver oncogenes.</p>
      <p>In these days, there are many reports about the efficacy of anti-PD-1 antibody for cutaneous melanoma patients and a potential association between the occurrence of a response and expression of PD-L1 in patients receiving nivolumab [<xref ref-type="bibr" rid="CR10">10</xref>]. On the other hand, Robert et al. reported that regardless of PD-L1 status, nivolumab-treated patients had improved overall survival, as compared with dacarbazine-treated patients [<xref ref-type="bibr" rid="CR19">19</xref>]. Although our findings did not show the positivity of PD-L1 in the two cases, there is still the possibility of the efficacy of immunotherapy for primary pulmonary melanoma, as the role of PD-1/PD-L1 pathway in primary pulmonary melanoma is yet to be investigated.</p>
    </sec>
    <sec id="Sec7" sec-type="conclusions">
      <title>Conclusions</title>
      <p>In conclusion, we encountered two cases of malignant melanoma of the lung that did not carry activating mutations in the <italic>BRAF</italic> gene. Further molecular analyses may uncover the characteristics of primary malignant melanoma.</p>
    </sec>
    <sec id="Sec8">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor in chief of this journal.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>PD-1</term>
          <def>
            <p>Programmed death 1</p>
          </def>
        </def-item>
        <def-item>
          <term>PD-L1</term>
          <def>
            <p>Programmed death ligand 1</p>
          </def>
        </def-item>
        <def-item>
          <term>PET-CT</term>
          <def>
            <p>Positron emission tomography-computed tomography</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>MW, HY, ST, and SM conceived the project. MW and SH performed the experiments. MW, HY, JS, SS, and ST collected the data and assisted with the experiments. MW, HY, and SH analyzed the data. MW, HY, SH, JS, and ST prepared the manuscript with input from the other authors. ST and SM supervised the project. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank Dr. Takehiro Matsubara (Biobank of Okayama University Hospital, Okayama, Japan) for his technical support and Dr. Noriyuki Tanaka (Department of Pathology, Okayama University Hospital) for providing advice.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilson</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Moran</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Primary melanoma of the lung: a clinicopathologic and immunohistochemical study of eight cases</article-title>
          <source>Am J Surg Pathol</source>
          <year>1997</year>
          <volume>21</volume>
          <fpage>1196</fpage>
          <lpage>202</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-199710000-00010</pub-id>
          <pub-id pub-id-type="pmid">9331292</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maeda</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Isowa</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Onuma</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Miura</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tokuyasu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kawasaki</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Primary malignant melanoma of the lung with rapid progression</article-title>
          <source>Gen Thorac Cardiovasc Surg</source>
          <year>2009</year>
          <volume>57</volume>
          <fpage>671</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1007/s11748-009-0454-9</pub-id>
          <pub-id pub-id-type="pmid">20013105</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bignell</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Edkins</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Clegg</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations of the BRAF gene in human cancer</article-title>
          <source>Nature</source>
          <year>2002</year>
          <volume>417</volume>
          <fpage>949</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="doi">10.1038/nature00766</pub-id>
          <pub-id pub-id-type="pmid">12068308</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Menzies</surname>
              <given-names>AMLT</given-names>
            </name>
            <name>
              <surname>Wilmott</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Hyman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kefford</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>O&#x2019;Toole</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intrapatient homogeneity of BRAF<sup>V600E</sup> expression in melanoma</article-title>
          <source>Am J Surg Pathol</source>
          <year>2014</year>
          <volume>38</volume>
          <fpage>377</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="doi">10.1097/PAS.0000000000000136</pub-id>
          <pub-id pub-id-type="pmid">24335665</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schreiber</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Old</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Smyth</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Cancer immunoediting: integrating immunity&#x2019;s roles in cancer suppression and promotion</article-title>
          <source>Science</source>
          <year>2011</year>
          <volume>331</volume>
          <fpage>1565</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1203486</pub-id>
          <pub-id pub-id-type="pmid">21436444</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Topalian</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Hodi</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Brahmer</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Gettinger</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>McDermott</surname>
              <given-names>DF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety, activity, and immune correlates of anti&#x2013;PD-1 antibody in cancer</article-title>
          <source>N Engl J Med</source>
          <year>2012</year>
          <volume>366</volume>
          <fpage>2443</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1200690</pub-id>
          <pub-id pub-id-type="pmid">22658127</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamamoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shigematsu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nomura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lockwood</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Okumura</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PIK3CA mutations and copy number gains in human lung cancers</article-title>
          <source>Cancer Res</source>
          <year>2008</year>
          <volume>68</volume>
          <fpage>6913</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5084</pub-id>
          <pub-id pub-id-type="pmid">18757405</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="other">cBioPortal for Cancer Genomics.&#xA0;[<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/">http://www.cbioportal.org/</ext-link>].</mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taube</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Anders</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>McMiller</surname>
              <given-names>TL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape</article-title>
          <source>Sci Transl Med</source>
          <year>2012</year>
          <volume>4</volume>
          <fpage>27</fpage>
          <lpage>37</lpage>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wolchok</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Kluger</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Callahan</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Postow</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Rizvi</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Lesokhin</surname>
              <given-names>AM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nivolumab plus ipilimumab in advanced melanoma</article-title>
          <source>N Engl J Med</source>
          <year>2013</year>
          <volume>369</volume>
          <fpage>122</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1302369</pub-id>
          <pub-id pub-id-type="pmid">23724867</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Committee for Scientific Affairs TJAfTS</collab>
            <name>
              <surname>Masuda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kuwano</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Okumura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Amano</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Arai</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thoracic and cardiovascular surgery in Japan during 2012 : annual report by the Japanese association for thoracic surgery</article-title>
          <source>Gen Thorac Cardiovasc Surg</source>
          <year>2014</year>
          <volume>62</volume>
          <fpage>734</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="doi">10.1007/s11748-014-0464-0</pub-id>
          <pub-id pub-id-type="pmid">25355583</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jensen</surname>
              <given-names>OAEJ</given-names>
            </name>
          </person-group>
          <article-title>Primary malignant melanoma</article-title>
          <source>Scand J Respir Dis</source>
          <year>1967</year>
          <volume>48</volume>
          <fpage>127</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="pmid">5183297</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bajetta</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Del Vecchio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bernard-Marty</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vitali</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Buzzoni</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rixe</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Metastatic melanoma: chemotherapy</article-title>
          <source>Semin Oncol</source>
          <year>2002</year>
          <volume>29</volume>
          <fpage>427</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="doi">10.1053/sonc.2002.35238</pub-id>
          <pub-id pub-id-type="pmid">12407508</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Komatsu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kitamura</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Otsuka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Katakami</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Malignant melanoma of the lung: report of two cases</article-title>
          <source>Ann Thorac Cardiovasc Surg</source>
          <year>2011</year>
          <volume>17</volume>
          <fpage>170</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="doi">10.5761/atcs.cr.09.01523</pub-id>
          <pub-id pub-id-type="pmid">21597415</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gong</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X-Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>W-D</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>S-J</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>X-J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Primary pulmonary malignant melanoma. A clinicopathologic study of two cases</article-title>
          <source>Diagn Pathol</source>
          <year>2012</year>
          <volume>7</volume>
          <fpage>123</fpage>
          <pub-id pub-id-type="doi">10.1186/1746-1596-7-123</pub-id>
          <pub-id pub-id-type="pmid">22992473</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ouarssani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Atoini</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Reda</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lhou</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Rguibi</surname>
              <given-names>MI</given-names>
            </name>
          </person-group>
          <article-title>Malignant melanoma of the lung: a case report</article-title>
          <source>Pan Afr Med J</source>
          <year>2012</year>
          <volume>11</volume>
          <fpage>68</fpage>
          <pub-id pub-id-type="pmid">22655102</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chapman</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Hauschild</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Robert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Haanen</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Ascierto</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Larkin</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Improved survival with vemurafenib in melanoma with BRAF V600E mutation</article-title>
          <source>N Engl J Med</source>
          <year>2011</year>
          <volume>364</volume>
          <fpage>2507</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1103782</pub-id>
          <pub-id pub-id-type="pmid">21639808</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toyooka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mitsudomi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Soh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Aokage</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamane</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oto</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Molecular oncology of lung cancer</article-title>
          <source>Gen Thorac Cardiovasc Surg</source>
          <year>2011</year>
          <volume>59</volume>
          <fpage>527</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="doi">10.1007/s11748-010-0743-3</pub-id>
          <pub-id pub-id-type="pmid">21850578</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Long</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Brady</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dutriaux</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Maio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mortier</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nivolumab in previously untreated melanoma without BRAF mutation</article-title>
          <source>N Engl J Med</source>
          <year>2015</year>
          <volume>372</volume>
          <fpage>320</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1412082</pub-id>
          <pub-id pub-id-type="pmid">25399552</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
